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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of systemic and topical antifungal agents in people with chronic rhinosinusitis, including those with allergic fungal
rhinosinusitis (AFRS) and, if possible, AFRS exclusively.
The review will exclude patients in the immediate post-surgical period (within six weeks of sinus surgery).
B A C K G R O U N D
Description of the condition
This review will update and replace the previously published re-
view ’Topical and systemic antifungal therapy for the symptomatic
treatment of chronic rhinosinusitis’ (Sacks 2011).
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses. It is characterised by two or more symptoms,
one of which must be nasal blockage/obstruction/congestion or
nasal discharge (anterior/posterior nasal drip) and one of facial
pain/pressure and/or reduction or loss of sense of smell. Symptoms
must have continued for at least 12 weeks. In addition, people
must have either mucosal changes within the ostiomeatal complex
or sinuses (or both) as evidenced by a computerised tomography
(CT) scan and/or endoscopic signs of at least one of the following:
nasal polyps, mucopurulent discharge primarily from the middle
meatus or oedema/mucosal obstruction primarily in the middle
meatus (EPOS 2012).
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
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mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
There is much debate regarding the role of fungus in the aetiology
of chronic rhinosinusitis. Intranasal fungus canbe demonstrated in
nearly all diseased and normal sinuses (Braun 2003; Lackner 2005;
Ponikau 1999). The definition and categorisation of fungal rhi-
nosinusitis is still controversial but the most commonly accepted
system divides the condition into two: invasive and non-invasive
disease, based on histopathological evidence of tissue invasion by
fungi (Chakrabarti 2009). Invasive fungal disease is a unique en-
tity and represents angioinvasive fungal propagation in the im-
munocompromised host setting. This is not the common presen-
tation of chronic rhinosinusitis experienced by the vast majority
of chronic sinusitis patients. Treatments usually include surgery
followed by medical treatment (EPOS 2012).
Non-invasive fungal rhinosinusitis can be divided into two cate-
gories: a fungus ball (also known as mycetoma) and allergic fungal
rhinosinusitis (AFRS). A fungus ball is a fungal collection in an
abnormal sinus that usually produces only mild symptoms and
can be surgically removed. Patients with fungus balls will not be
included in this review.
AFRS is a well-recognised subgroup of chronic rhinosinusitis,
in which an IgE mediated hypersensitivity to fungal elements
drives the inflammatory process. Allergic fungal rhinosinusitis is
generally diagnosed using the Bent-Kuhn criteria (Bent 1994):
type I hypersensitivity confirmed by history, skin tests or serol-
ogy; nasal polyposis; characteristic CT scan (double density sign);
eosinophilic mucus without fungal invasion into sinus tissue; pos-
itive fungal stain of sinus contents removed intraoperatively or
during office endoscopy.
In addition to AFRS, there is some research to suggest that a
much broader group of patients with chronic rhinosinusitis with
an eosinophilic inflammationmay bemediated by fungal elements
and a subsequent cascade of immune effects through non-clas-
sical pathways (Sok 2006). Furthermore, since Bent and Kuhn
defined their subgroup of AFRS, further parallel groups have
been defined including eosinophilic fungal rhinosinusitis (EFRS)
and eosinophilic mucinous rhinosinusitis (EMRS). Patients with
eosinophilic fungal rhinosinusitis have been defined as those who
meet the Bent-Kuhn criteria for AFRS except for the IgEmediated
hypersensitivity to a fungal allergen. Patients with eosinophilic
mucinous rhinosinusitis are defined as those who meet the Bent-
Kuhn criteria for AFRS except that they have no positive fungal
culture or smear. The Bent andKuhn definition has beenmodified
to include immunocompetence, which replaces type 1 hypersen-
sitivity as a requirement (Philpott 2011).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptomshave ama-
jor impact on quality of life, reportedly greater in several domains
of the SF-36 than angina or chronic respiratory disease (Gliklich
1995). Acute exacerbations, inadequate symptom control and res-
piratory disease exacerbation are common.Complications are rare,
but may include visual impairment, bone erosion and expansion,
and intracranial infection (EPOS 2012). Chronic rhinosinusitis
affects an increasing proportion of the adult population until the
sixth decade of life and then declines (Chen 2003).
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically
(by mouth) and include steroids, antibiotics and saline. In the late
1990s some centres advocated the use of topical antifungals in
chronic rhinosinusitis patients (Ponikau 1999). Since then there
has been increasing controversy and contrasting papers have both
advocated and refuted the use of both topical and systemic anti-
fungal agents in the management of these patients (Ebbens 2007).
Description of the intervention
Antifungal agents can be used as systemic medications (orally or
intravenously) or as topical preparations delivered directly to the
sinuses. Topical treatments can be given using different delivery
systems such as douching, nebulisation, atomisation, inhalation,
irrigation, spray, drops or powder insufflations.
We will include all antifungals used in the management of inflam-
matory disease of the paranasal sinuses, both systemic and topical.
Examples of antifungal agents include amphotericin B, glucona-
zole, itraconazole, voriconazole and ketoconazole. These agents
may be fungistatic or fungicidal depending on the drug concen-
tration and the susceptibility of the fungus.
How the intervention might work
Antifungal agentswork in one of twoways, either as fungicides that
kill the fungus cells, or as fungistatics that inhibit the growth and
reproduction of the fungal cells. Although good research demon-
strates an interaction of the immune systemwith fungus in chronic
rhinosinusitis (Ponikau 2007), this does not necessarily imply that
antifungals will be effective in managing the disease. In analogy,
there is little plausibility in using anti-dust mite agents in man-
aging house dust mite allergic rhinitis. It is well-established that
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dust mite allergen can stimulate the same response in these pa-
tients. Similarly, in chronic rhinosinusitis the inappropriate im-
mune activation may be the driving pathologic mechanism and
fungal elements only the innocent target of the process. Fungus is
ubiquitous in both our environment and sinuses (Lackner 2005).
When taken orally (systemic) certain classes of antifungals, such
as the azoles, have the potential for adverse events such as gas-
trointestinal disturbances and they have also been associated with
serious adverse events, particularly with regard to hepatic and re-
nal toxicity. Topical amphotericin is expensive and also associated
with potential adverse events such as headache and local irritations
(Ebbens 2006).
Why it is important to do this review
The previous Cochrane Review and other more recent systematic
reviews have concluded that there is no convincing evidence to
support the use of antifungals in chronic rhinosinusitis (Mistry
2014; Sacks 2011). However, the authors of these reviews have
commented on the clinical diversity of the included populations
within the trials, particularly with regard to diagnosis. Often the
population includes patients with both chronic rhinosinusitis and
AFRS, as this distinction is ambiguous in some trials. It is im-
portant to understand whether there is a difference in treatment
effect between these two populations. Similarly, the existing re-
views include a heterogeneous population of people with respect
to sinus surgery prior to the start of the trial. We will not include
studies designed to evaluate interventions in the immediate peri-
surgical period, which are focused on assessing the impact of the
intervention on the surgical procedure or on modifying the post-
surgical results (preventing recurrence of chronic rhinosinusitis
symptoms).
This review is one of a suite of Cochrane Reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Chong 2016c; Head 2016a; Head
2016b; Head 2016c), and we will use the same methods and out-
come measures as have been used across these reviews.
This systematic review will aim to look at the balance of benefits
and harms for both systemic and topical antifungal agents in the
treatment of people with chronic rhinosinusitis.
O B J E C T I V E S
To assess the effects of systemic and topical antifungal agents in
people with chronic rhinosinusitis, including those with allergic
fungal rhinosinusitis (AFRS) and, if possible, AFRS exclusively.
The review will exclude patients in the immediate post-surgical
period (within six weeks of sinus surgery).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials will only be
included if the data from the first phase are available); and
• patients were followed up for at least two weeks.
We will exclude studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
People (adults and children) with chronic rhinosinusitis, whether
with polyps or without polyps. This includes the subgroups of
people with a diagnosis of allergic fungal rhinosinusitis (AFRS),
eosinophilic fungal rhinosinusitis (EFRS) or eosinophilic muci-
nous rhinosinusitis (EMRS).
We will exclude studies that included a majority of patients with:
• cystic fibrosis;
• aspirin-exacerbated respiratory disease (aka Samter’s triad);
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps and inverted papilloma;
• primary ciliary dyskinesia;
• invasive fungal disease in the sinuses;
• fungus ball;
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Fungus can be demonstrated in almost all diseased and normal
sinuses (Lackner 2005), thus we will not set associated fungus con-
firmed either histologically or on culture as an inclusion criteria.
The immunological role of the fungus and the host is still an area
of ongoing research.
Patients with chronic rhinosinusitis will be included if they fulfil
the criteria defined by EPOS (EPOS 2012).
In order to identify patients with AFRS for subgroup analysis, we
will use the modified Bent-Kuhn criteria (Philpott 2011), where
a patient must fulfil the following criteria:
• type I hypersensitivity confirmed by history, skin tests or
serology OR immunocompromise;
• nasal polyposis;
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• characteristic CT scan (double density sign);
• eosinophilic mucus without fungal invasion into sinus
tissue;
• positive fungal stain of sinus contents removed
intraoperatively or during office endoscopy.
We will identify patients with EFRS for subgroup analysis if they
meet the criteria for AFRS (above) except for the presence of hy-
persensitivity to a fungal allergen.
We will identify patients with EMRS for subgroup analysis if they
meet the criteria for AFRS (above) except that they do not have a
positive fungal culture/smear.
Types of interventions
We will include the following groups of topical or systemic anti-
fungals:
• polyene antifungals (e.g. amphotericin);
• imidazole, triazole and thiazole antifungals (e.g.
itraconazole);
• allylamines;
• echinocandins.
We will include both topically applied and systemic antifungals
in the review. We will include any dose and delivery method. The
minimum duration of treatment is 28 days.
Comparisons
The comparators are:
• placebo or no intervention;
• another class of antifungals;
• the same type of antifungal, which is either:
◦ given for a different duration;
◦ given at a different dose;
• other treatments for chronic rhinosinusitis, including:
◦ intranasal corticosteroids;
◦ oral/systemic steroids;
◦ antibiotics;
◦ nasal saline irrigation.
Concurrent treatments will be allowed if they are used in both
treatment arms; they include, for example:
• nasal saline irrigation only;
• intranasal corticosteroids only;
• intranasal corticosteroids plus antibiotics;
• intranasal corticosteroids plus nasal irrigation plus oral
steroids;
• other combinations.
Comparison pairs
There will be multiple possible comparison pairs due to the large
number of interventions allowed.
The main comparison pairs of interest will be:
• topical antifungalsversus no antifungal intervention or
placebo;
• systemic antifungals versus no antifungal intervention or
placebo;
• topical antifungals versus no intervention or placebo
alongside intranasal steroids or other standard treatment in all
arms of the trial.
Other possible comparison pairs will include:
• antifungals versus intranasal steroids;
• antifungals versus oral/systemic steroids;
• antifungals class A versus antifungals class B;
• antifungal A with duration of treatment X versus antifungal
A with duration of treatment Y;
• antifungal A at dose X versus antifungal A at dose Y.
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, patient-reported individual symptom scores will be
reported for the following symptoms: nasal obstruction/
blockage/congestion, nasal discharge (rhinorrhoea), facial
pressure/pain, loss of sense of smell (adults) and cough (children).
• Significant adverse effects: hepatic toxicity (systemic
antifungals).
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: gastrointestinal disturbances, allergic
reactions (systemic antifungals).
• Other adverse effects: epistaxis, headache, local discomfort
(e.g. itching, mild burning) (topical antifungals).
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
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Both short-term (at the end of treatment) and long-term effects
are important therefore we will evaluate outcomes at the end of
treatment or within four weeks, at four weeks to six months, six
to 12 months and more than 12 months. For adverse events we
will analyse data from the longest time periods.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct system-
atic searches for randomised controlled trials and controlled clin-
ical trials. There will be no language, publication year or publica-
tion status restrictions. We may contact original authors for clar-
ification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane ENT Trials Register;
• the Cochrane Register of Studies Online;
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R);
• Ovid Embase;
• Ovid CAB Abstracts;
• EBSCO CINAHL;
• LILACS, lilacs.bvsalud.org;
• KoreaMed;
• IndMed, www.indmed.nic.in;
• PakMediNet, www.pakmedinet.com;
• Web of Knowledge, Web of Science;
• ClinicalTrials.gov;
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp;
• ISRCTN, www.isrctn.com;
• Google Scholar, scholar.google.co.uk;
• Google, www.google.com.
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of the
highly sensitive search strategy designed by theCochrane Collabo-
ration for identifying randomised controlled trials and controlled
clinical trials (as described in the Cochrane Handbook for System-
atic Reviews of Interventions Version 5.1.0, Box 6.4.b. (Handbook
2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search Ovid MEDLINE, theCochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we can scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
At least two review authors (KH, PLS, LYC) will independently
screen all titles and abstracts of the studies obtained from the
database searches to identify potentially relevant studies. At least
two review authors (KH, PLS, LYC) will evaluate the full text of
each potentially relevant study to determine whether it meets the
inclusion and exclusion criteria for this review.
We will resolve any differences by discussion and consensus, with
the involvement of a third author for clinical and methodological
input where necessary.
Data extraction and management
At least two review authors (KH, PLS, LYC) will independently
extract data from each study using a standardised data collection
form (see Appendix 2).Whenever a study has more than one pub-
lication, we will retrieve all publications to ensure complete extrac-
tion of data.Where there are discrepancies in the data extracted by
different review authors, we will check these against the original
reports and will resolve differences by discussion and consensus,
with the involvement of a third author or a methodologist where
appropriate. We will contact the original study authors for clari-
fication or for missing data whenever possible. If differences are
found between publications of a study, we will contact the original
authors for clarification. We will use data from the main paper(s)
if no further information is found.
We will include key characteristics of the studies, such as study
design, setting, sample size, population and how outcomes were
defined or collected in the studies. In addition, we will also collect
baseline information on prognostic factors or effect modifiers. For
this review, this will include:
• presence or absence of allergic fungal rhinosinusitis (AFRS),
eosinophilic fungal rhinosinusitis (EFRS) and eosinophilic
mucinous rhinosinusitis (EMRS);
• presence or absence of nasal polyps and baseline nasal polyp
score where appropriate;
• presence of eosinophilic chronic rhinosinusitis;
• whether the patient has had previous sinus surgery.
We will also note down whether studies only selected patients with
known AFRS and how this was identified.
For the outcomes of interest to the review, we will extract the
findings of the studies on an available case analysis basis; i.e. we
will include data from all patients available at the time points
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based on the treatment randomisedwhenever possible, irrespective
of compliance or whether patients had received the treatment as
planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we will extract the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data are not available, we will extract the values for
change from baseline. We will analyse data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appear to be approximately
normally distributed or if the analysis that the investigators
performed suggested parametric tests were appropriate, then we
will treat the outcome measures as continuous data. Alternatively,
if data are available, we plan to convert into binary data.
We have prespecified the time points of interest for the outcomes
in this review. While studies may have reported data at multiple
time points, we will only extract the longest available data within
the time points of interest. For example, for ’short’ follow-up pe-
riods, our time point is defined as ’three to six months’ post-ran-
domisation. If a study reports data at three, four and six months,
we will only extract and analyse the data for the six-month follow-
up.
Extracting data from figures
Where values for primary or secondary outcomes are shown as
figures within the paper we will contact the study authors to try
to obtain the raw values. When the raw values are not provided,
we will extract information from the graphs using an online data
extraction tool (http://arohatgi.info/WebPlotDigitizer/app/), us-
ing the best quality version of the relevant figures available.
Assessment of risk of bias in included studies
At least two review authors (KH, PLS, LYC) will independently
assess the risk of bias of each included study. We will follow the
guidance in the Cochrane Handbook for Systematic Reviews of In-
terventions (Handbook 2011), and we will use the Cochrane ’Risk
of bias’ tool. With this tool we will assess the risk of bias as ’low’,
’high’ or ’unclear’ for each of the following six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
Wewill summarise the effects of dichotomous outcomes (e.g. pro-
portion of patients with symptom resolution) as risk ratios (RR)
with CIs. For the key outcomes that we will present in the ’Sum-
mary of findings’ table, we will also express the results as absolute
numbers based on the pooled results and compared to the assumed
risk.We also plan to calculate the number needed to treat to benefit
(NNTB) using the pooled results. The assumed baseline risk will
typically be either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies are available, and
where appropriate, we also plan to present additional data based
on the assumed baseline risk in (c) a low-risk population and (d)
a high-risk population.
For continuous outcomes, we will express treatment effects as a
mean difference (MD) with standard deviation (SD). If different
scales are used to measure the same outcome we will use the stan-
dardised mean difference (SMD), and we will provide a clinical
interpretation of the SMD values.
Unit of analysis issues
This review will not use data from phase II of cross-over studies or
from studies where the patient is not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we find cluster-randomised trials, we will analyse these according
to the methods in section 16.3.3 of the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011).
Dealing with missing data
We will contact study authors via email whenever the outcome of
interest is not reported, if themethods of the study suggest that the
outcome had been measured. We will do the same if not all data
required for meta-analysis are reported, unless the missing data are
standard deviations. If standard deviation data are not available,
we will approximate these using the standard estimation methods
from P values, standard errors or 95% CIs if these are reported,
as detailed in the Cochrane Handbook for Systematic Reviews of
Interventions (Handbook 2011).Where it is impossible to estimate
these, we will contact the study authors.
Apart from imputations for missing standard deviations, we will
not conduct any other imputations. However, we will complete
calculations relating to disease severity (measured by patient-re-
ported symptom scores) as some studies may measure individual
symptoms rather than using validated instruments (see ’Imputing
total symptom scores’ below). We will extract and analyse data for
all outcomes using the available case analysis method.
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Imputing total symptom scores
Where a paper does not present information for the total disease
severity in terms of patient-reported symptom scores but presents
data for the results of individual symptoms, we will use the symp-
toms covering the important domains of the EPOS chronic rhi-
nosinusitis diagnosis criteria (EPOS 2012), to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusi-
tis require at least two symptoms. One of the symptoms must
be either nasal blockage or nasal discharge; other symptoms can
include facial pressure/pain, loss of sense of smell (for adults) or
cough (for children). Where mean final values or changes from
baseline are presented in the paper for the individual symptoms
we will sum these to calculate a ’total symptom score’. We will
calculate standard deviations for the total symptom score as if the
symptomswere independent, randomvariables thatwere normally
distributed. We acknowledge that there is likely to be a degree of
correlation between the individual symptoms, however we will use
this process as themagnitude of correlation between the individual
symptoms is not currently well understood (no evidence found). If
the correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method of
calculation will underestimate the standard deviation of the total
score. However, the average patient-reported symptom scores have
a correlation coefficient of about 0.5; if this is also applicable to
chronic rhinosinusitis symptoms, the method used should have
minimal impact (Balk 2012). As this method of calculation does
not take into account weighting of different symptoms (no evi-
dence found), we will downgrade all the disease severity outcomes
in GRADE for lack of use of validated scales where this occurs.
Assessment of heterogeneity
We will assess clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We will assess statistical heterogeneity by visually inspecting the
forest plots and by considering the Chi² test (with a significance
level set at P value < 0.10) and the I² statistic, which calculates
the percentage of variability that is due to heterogeneity rather
than chance, with I² values over 50% suggesting substantial het-
erogeneity (Handbook 2011).
Assessment of reporting biases
Wewill assess reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We will assess within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this can be obtained. If the protocol is not available, we
will compare the outcomes reported to those listed in the methods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We will try to find further information from the
study authors. If no further information can be obtained, we will
note this as being a high risk of bias. Where there is insufficient
information to judge the risk of bias, we will note this as an unclear
risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We plan to create funnel plots if sufficient trials (more than 10)
are available for an outcome. If we observe asymmetry of the fun-
nel plot, we plan to conduct more formal investigation using the
methods proposed by Egger 1997.
Data synthesis
We will conduct all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we plan to analyse treat-
ment differences as a risk ratio (RR) calculated using the Mantel-
Haenszel methods. We plan to analyse time-to-event data using
the generic inverse variance method.
For continuous outcomes, if all the data are from the same scale,
we plan to pool mean values obtained at follow-up with change
outcomes and report this as aMD. However, if the SMD has to be
used as an effect measure, we will not pool change and endpoint
data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
We plan to conduct some subgroup analyses regardless of whether
statistical heterogeneity is observed, as these are widely suspected
to be potential effect modifiers. For this review, this includes:
• Presence of allergic fungal rhinosinusitis (as defined by the
modified Bent-Kuhn criteria; see Types of participants), EFRS
and EMRS. People with AFRS may respond differently to
antifungal agents as in AFRS an IgE mediated hypersensitivity to
fungal elements drives the inflammatory process.
• Phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, a mixed group or the status of polyps is not known
or not reported. We planned to undertake the subgroup analysis
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as although there appears to be a considerable overlap between
the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
Fokkens 2007; Ragab 2004; Ragab 2010; van Drunen 2009),
there is some evidence pointing to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011). The role
of fungi in the pathology is also unclear and this makes it
uncertain whether antifungals will have similar effects.
• Eosinophilic versus non-eosinophilic chronic rhinosinusitis.
Some researchers hypothesise that patients with eosinophilic
chronic rhinosinusitis will form an eosinophilic reaction towards
the fungi present in their sinonasal mucin. It is proposed that
this reaction will subsequently be involved in the inflammatory
response (Ponikau 1999).
We plan to present the main analyses of this review according to
the subgroups of presence of AFRS. We intend to present all other
subgroup analysis results in tables.
When studies have a mixed group of patients, we plan to analyse
the study as one of the subgroups (rather than as a mixed group) if
more than 80% of patients belong to one category. For example,
if 81% of patients have AFRS, we will analyse the study as that
subgroup.
In addition to the subgroups above, we plan to conduct the follow-
ing subgroup analyses in the presence of statistical heterogeneity:
• patient age (children versus adults);
• dose;
• duration of treatment;
• method of delivery;
• class of antifungal agent.
Sensitivity analysis
We plan to carry out sensitivity analyses to determine whether
the findings are robust to the decisions made in the course of
identifying, screening and analysing the trials. We plan to conduct
sensitivity analysis for the following factors, whenever possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we will define these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed));
• how outcomes were measured: we plan to investigate the
impact of including data where the validity of the measurement
was unclear.
If any of these investigations find a difference in the size of the
effect or heterogeneity, we will mention this in the ’Effects of
interventions’ section.
GRADE and ’Summary of findings’ table
Using the GRADE approach, at least two review authors (KH,
PLS, LYC) will independently rate the overall quality of evidence
using the GDT tool (http://www.guidelinedevelopment.org/) for
the main comparison pairs listed in the Types of interventions sec-
tion. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we will apply
this in the interpretation of results. There are four possible ratings:
’high’, ’moderate’, ’low’ and ’very low’. A rating of ’high’ quality
evidence implies that we are confident in our estimate of effect
and that further research is very unlikely to change our confidence
in the estimate of effect. A rating of ’very low’ quality implies that
any estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ tables will present only the top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, adverse effects and generic quality of life score). We
will not include the outcomes endoscopic score or CT scan score
in the ’Summary of findings’ tables.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
CRSO MEDLINE (Ovid) Embase (Ovid) Web of Science (Web of
Knowledge)
#1
MESH DESCRIPTOR Rhini-
tis EXPLODE ALL TREES
#2 MESH DESCRIP-
TOR Paranasal Sinus Diseases
EXPLODE All TREES
#3 MESH DE-
SCRIPTOR Paranasal Sinuses
EXPLODE All TREES
#4 (rhinosinusitis or nasosi-
nusitis or pansinusitis or eth-
moiditis or sphenoiditis):TI,
AB,KY
#5 (kartagener* near
syndrome*):TI,AB,KY
#6 (inflamm* near sinus*):TI,
AB,KY
#7 ((maxilla* or frontal*) near
sinus*):TI,AB,KY
#8 #1 OR #2 OR #3 OR #4
OR #5 OR #6 OR #7
#9 MESH
DESCRIPTOR Chronic Dis-
ease EXPLODE All TREES
#10
MESH DESCRIPTOR Recur-
rence EXPLODE All TREES
#11 MESH DESCRIPTOR
Fungi EXPLODE All TREES
#12
MESH DESCRIPTOR Myce-
toma EXPLODE All TREES
#13 (chronic or persis* or re-
current* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*):TI,AB,KY
#14 #9 OR #10 OR #11 OR #
12 OR #13
#15 #8 AND #14
#16 (CRSsNPor AFS or AFRS)
:TI,AB,KY
1 exp Rhinitis/
2 exp Paranasal Sinuses/
3 exp Paranasal Sinus Diseases/
4 (rhinosinusitis or nasosinusi-
tis or pansinusitis or ethmoidi-
tis or sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*)
.ab,ti.
6 (inflamm* adj3 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 si-
nus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp Chronic Disease/
10 exp Recurrence/
11 exp Fungi/
12 exp Mycetoma/
13 (chronic or persis* or recur-
rent* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*).ab,ti
14 9 or 10 or 11 or 12 or 13
15 8 and 14
16 (CRSsNP or AFS or AFRS)
.ab,ti.
17 ((sinusitis or rhinitis) adj3
(chronic or persis* or recurrent*
or fung*)).ab,ti
18 15 or 16 or 17
19 exp Nasal Polyps/
20 exp Paranasal Sinus Dis-
eases/mi [Microbiology]
21 exp rhinitis/mi [Microbiol-
ogy]
22 exp Nasal Mucosa/mi [Mi-
crobiology]
23 exp Paranasal Sinuses/mi
[Microbiology]
24 exp Nose/
25 exp Nose Diseases/
26 24 or 25
1 exp rhinitis/
2 exp Paranasal Sinuses/
3 exp Paranasal Sinus Diseases/
4 (rhinosinusitis or nasosinusi-
tis or pansinusitis or ethmoidi-
tis or sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*)
.ab,ti.
6 (inflamm* adj3 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 si-
nus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp Chronic Disease/
10 exp Recurrence/
11 exp Fungi/
12 exp Mycetoma/
13 (chronic or persis* or recur-
rent* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*).ab,ti
14 9 or 10 or 11 or 12 or 13
15 8 and 14
16 (CRSsNP or AFS or AFRS)
.ab,ti.
17 ((sinusitis or rhinitis) adj3
(chronic or persis* or recurrent*
or fung*)).ab,ti
18 15 or 16 or 17
19 exp Nasal Polyps/
20 exp Nose/
21 exp Nose Diseases/
22 20 or 21
23 exp Polyps/
24 22 and 23
25 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
adj3 (papilloma* or polyp* or
fung*)).ab,ti
26 (rhinopolyp* or CRSwNP).
S1 TOPIC: ((rhinosinusitis or
nasosinusitis or pansinusitis or
ethmoiditis or sphenoiditis))
S2 TOPIC: ((kartagener* near/
3 syndrome*))
S3 TOPIC: ((inflamm* near/3
sinus*))
S4TOPIC: ((maxilla* near/3 si-
nus*))
S5 TOPIC: ((frontal* near/3 si-
nus*))
S6 #5OR#4OR#3OR#2OR
#1
S7 TOPIC: ((chronic or per-
sis* or recurrent* or fung* or
eosinophil* or mycetoma* or
Maduromycos* or Actinomyce-
toma* or Eumycetoma*))
S8 #7 AND #6
S9 TOPIC: (CRSsNP or AFS
or AFRS)
S10 TOPIC: (sinusitis near/3
chronic)
S11 TOPIC: (sinusitis near/3
persis*)
S12 TOPIC: (sinusitis near/3
recurrent*)
S13 TOPIC: (sinusitis near/3
fung*)
S14 TOPIC: (rhinitis near/3
fung*)
S15TOPIC: (rhinitis near/3 re-
current*)
S16 TOPIC: (rhinitis near/3
persis*)
S17 TOPIC: (rhinitis near/3
chronic)
S18 #17 OR #16 OR #15 OR
#14 OR #13 OR #12 OR #11
OR #10 OR #9 OR #8
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#17 ((sinusitis or rhinitis) near
(chronic or persis* or recurrent*
or fung*)):TI,AB,KY
#18 #15 OR #16 OR #17
#19 MESH DESCRIPTOR
Nasal Polyps EXPLODE All
TREES
#20 MESH DESCRIPTOR
Paranasal Sinus Diseases EX-
PLODE ALL TREES WITH
QUALIFIERS MI
#21 MESH DESCRIP-
TOR Rhinitis EXPLODE ALL
TREES WITH QUALIFIERS
MI
#22 MESH DESCRIPTOR
Paranasal Sinuses EXPLODE
ALL TREES WITH QUALI-
FIERS MI
#23 MESH DESCRIPTOR
Nasal Mucosa EXPLODE ALL
TREES WITH QUALIFIERS
MI
#24 MESH DESCRIPTOR
Nose EXPLODE ALL TREES
#25 MESH DESCRIPTOR
Nose Diseases EXPLODE ALL
TREES
#26 #24 OR #25
#27
MESH DESCRIPTOR Polyps
EXPLODE ALL TREES
#28 #26 AND #27
#29 (rhinopolyp* or CRSwNP)
:TI,AB,KY
#30 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
near (papilloma* or polyp* or
fung*)):TI,AB,KY
#31 #18 OR #19 OR #20 OR
#21 OR #22 OR #23 OR #28
OR #29 OR #30
#32 MESH DESCRIPTOR
Antifungal Agents EXPLODE
All TREES
#33 (antifung* or “anti fung*”
or fungastic or fungicidal or
Fungizone or Amphocil or
Zonal or Diflucan or Triflucan
27 exp Polyps/
28 26 and 27
29 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
adj3 (papilloma* or polyp* or
fung*)).ab,ti
30 (rhinopolyp* or CRSwNP).
ab,ti.
31 18 or 19 or 20 or 21 or 22
or 23 or 28 or 29 or 30
32 exp Antifungal Agents/ or
exp Amphotericin B/ or exp
Antimycin A/ or exp Azaser-
ine/ or exp Benzoates/ or exp
Brefeldin A/ or exp Candi-
cidin/ or exp Cerulenin/ or
expClotrimazole/ or expCyclo-
heximide/ or exp Cyclosporine/
or exp Dichlorophen/ or exp
Echinocandins/ or exp Econa-
zole/ or exp Filipin/ or exp Flu-
conazole/ or exp Flucytosine/ or
exp Griseofulvin/ or exp Hex-
etidine/ or exp Itraconazole/
or exp Ketoconazole/ or exp
Lucensomycin/ or exp Mepar-
tricin/ or exp Miconazole/ or
exp Monensin/ or exp My-
cobacillin/ or exp Natamycin/
or exp Nifuratel/ or exp Nys-
tatin/ or exp Pentamidine/ or
exp Rutamycin/ or exp Salicylic
Acid/ or exp Sirolimus/ or exp
Sodium Benzoate/ or exp Thy-
mol/ or exp Tomatine/ or exp
Tolnaftate/ or exp Triacetin/ or
exp Trimetrexate/ or exp Ventu-
ricidins/
33 exp Mycoses/dt, th [Drug
Therapy, Therapy]
34 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole).ab,ti,
ab,ti.
27 18 or 19 or 24 or 25 or 26
28 exp Antifungal Agents/
29 exp Amphotericin B/
30 exp Antimycin A/
31 exp Azaserine/
32 exp Benzoates/
33 exp Brefeldin A/
34 exp Candicidin/
35 exp Cerulenin/
36 exp Clotrimazole/
37 exp Cycloheximide/
38 exp Cyclosporine/
39 exp Dichlorophen/
40 exp Echinocandins/
41 exp Econazole/
42 exp Filipin/
43 exp Fluconazole/
44 exp Flucytosine/
45 exp Griseofulvin/
46 exp Hexetidine/
47 exp Itraconazole/
48 exp Ketoconazole/
49 exp Lucensomycin/
50 exp Mepartricin/
51 exp Miconazole/
52 exp Monensin/
53 exp Mycobacillin/
54 exp Natamycin/
55 exp Nifuratel/
56 exp Nystatin/
57 exp Pentamidine/
58 exp Rutamycin/
59 exp Salicylic Acid/
60 exp Sirolimus/
61 exp Sodium Benzoate/
62 exp Thymol/
63 exp Tomatine/
64 exp Tolnaftate/
65 exp Triacetin/
66 exp Trimetrexate/
67 exp Venturicidins/
68 exp mycosis/dt, th [Drug
Therapy, Therapy]
69 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
S19 TOPIC: (nose near/3 pa-
pilloma*)
S20 TOPIC: (nose near/3
polyp*)
S21 TOPIC: (nose near/3
fung*)
S22 TOPIC: (nasal near/3
fung*)
S23 TOPIC: (nasal near/3
polyp*)
S24 TOPIC: (nasal near/3 pa-
pilloma*)
S25 TOPIC: (rhino* near/3 pa-
pilloma*)
S26 TOPIC: (rhino* near/3
polyp*)
S27 TOPIC: (rhino* near/3
fung*)
S28 TOPIC: (rhinitis near/3
fung*)
S29 TOPIC: (rhinitis near/3
polyp*)
S30 TOPIC: (rhinitis near/3
papilloma*)
S31 TOPIC: (sinus* near/3 pa-
pilloma*)
S32 TOPIC: (sinus* near/3
polyp*)
S33 TOPIC: (sinus* near/3
fung*)
S34 TOPIC: (sinonasal near/3
fung*)
S35 TOPIC: (sinonasal near/3
polyp*)
S36 TOPIC: (sinonasal near/3
papilloma*)
S37 TOPIC: (rhinopolyp* or
CRSwNP)
S38 #37 OR #36 OR #35 OR
#34 OR #33 OR #32 OR #31
OR #30 OR #29 OR #28 OR
#27 OR #26 OR #25 OR #24
OR #23 OR #22 OR #21 OR
#20 OR #19 OR #18
S39 TOPIC: (acivicin or ajoene
or amorolfin or Amphotericin
or anidulafungin or Antimycin
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or hexal or Fluco* or Flunazul
or Fungata or Lavisa or Loitin
or Neofomiral or oxifungol or
Solacap or 49858 of BÈagyne or
51211 or Sporanox orOrungal)
:TI,AB,KY
#34 MESH DESCRIP-
TORMycoses EXPLODEALL
TREES WITH QUALIFIERS
DT,TH
#35 MESH DESCRIPTOR
Venturicidins EXPLODE All
TREES
#36 MESH DESCRIPTOR
Trimetrexate EXPLODE All
TREES
#37 MESH DESCRIP-
TOR Triacetin EXPLODE All
TREES
#38 MESH
DESCRIPTOR Tolnaftate EX-
PLODE All TREES
#39
MESH DESCRIPTOR Toma-
tine EXPLODE All TREES
#40 MESH DESCRIP-
TOR Thymol EXPLODE All
TREES
#41 MESH DESCRIPTOR
Sodium Benzoate EXPLODE
All TREES
#42 MESH DESCRIP-
TOR Sirolimus EXPLODE All
TREES
#43 MESH DESCRIPTOR
Salicylic Acid EXPLODE All
TREES
#44 MESH DESCRIPTOR
Pentamidine EXPLODE All
TREES
#45 MESH DESCRIP-
TOR Nystatin EXPLODE All
TREES
#46 MESH DESCRIP-
TOR Nifuratel EXPLODE All
TREES
#47 MESH DESCRIP-
TOR Natamycin EXPLODE
All TREES
nm
35 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic adj3
acid) or (diallyl adj3 trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
or Econazole or Ethonium or
fenticonazole or ferroin or Fil-
ipin or Fluconazole or Flucyto-
sine or glyphosate or Griseoful-
vin or hamycin or Hexetidine
or hydroxyitraconazole or (ICI
adj3 “195739”) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic adj3 acid) or Pen-
tamidine or polygodial or (poly-
oxin adj3 D) or posaconazole
or (potassium adj3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sal-
icylhydroxamic adj3 acid) or
(Salicylic adj3 Acid) or saper-
conazole or (Sch adj3 “39304”)
or sertaconazole or sinefungin
or Sirolimus or (Sodium adj3
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole).tw
70 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic adj3
acid) or (diallyl adj3 trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
or Econazole or Ethonium or
fenticonazole or ferroin or Fil-
ipin or Fluconazole or Flucyto-
sine or glyphosate or Griseoful-
vin or hamycin or Hexetidine
or hydroxyitraconazole or (ICI
adj3 “195739”) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic adj3 acid) or Pen-
tamidine or polygodial or (poly-
oxin adj3 D) or posaconazole
or (potassium adj3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sal-
icylhydroxamic adj3 acid) or
(Salicylic adj3 Acid) or saper-
conazole or (Sch adj3 “39304”)
or sertaconazole or sinefungin
or artemether or aureobasidin
or Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole)
S40 TOPIC: (Candicidin or
candidin or captax or caspofun-
gin or Cerulenin or ciclopirox
or cilofungin or Clotrimazole
or compactin or cordycepin or
cryptophycin orCycloheximide
or Cyclosporine)
S41 TOPIC: (decanoic near/3
acid)
S42 TOPIC: (diallyl near/3
trisulfide)
S43 TOPIC: (Dichlorophen or
diucifon or echinocandin or
Echinocandins or Econazole or
Ethonium or fenticonazole or
ferroin or Filipin or Fluconazole
or Flucytosine or glyphosate
or Griseofulvin or hamycin or
Hexetidine or hydroxyitracona-
zole)
S44 TOPIC: (ICI near/3
“195739”)
S45 TOPIC: (isoconazole or
Itraconazole or iturin or jas-
plakinolide or Ketoconazole
or lactoferricin or lapachol
or lawsone or leptomycin or
Lucensomycin or Mepartricin
or methylamphotericin or mi-
cafungin or Miconazole or
miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Nifu-
ratel or nikkomycin or nitroxo-
line or Nystatin or oxiconazole
or papulacandin)
S46 TOPIC: (pelargonic near/
3 acid)
S47 TOPIC: (Pentamidine or
polygodia)
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#48 MESH DESCRIPTOR
Mycobacillin EXPLODE All
TREES
#49 MESH
DESCRIPTORMonensin EX-
PLODE All TREES
#50 MESH DESCRIP-
TOR Miconazole EXPLODE
All TREES
#51 MESH DESCRIPTOR
Mepartricin EXPLODE All
TREES
#52 MESH DESCRIPTOR
Lucensomycin EXPLODE All
TREES
#53 MESH DESCRIPTOR
Ketoconazole EXPLODE All
TREES
#54 MESH DESCRIPTOR
Itraconazole EXPLODE All
TREES
#55
MESH DESCRIPTOR Hexe-
tidine EXPLODE All TREES
#56 MESH DESCRIPTOR
Griseofulvin EXPLODE All
TREES
#57
MESH DESCRIPTOR Flucy-
tosine EXPLODE All TREES
#58 MESH DESCRIPTOR
Fluconazole EXPLODE All
TREES
#59 MESH
DESCRIPTOR Econazole EX-
PLODE All TREES
#60 MESH DESCRIPTOR
Echinocandins EXPLODE All
TREES
#61 MESH DESCRIPTOR
Dichlorophen EXPLODE All
TREES
#62 MESH DESCRIPTOR
Cyclosporine EXPLODE All
TREES
#63 MESH DESCRIPTOR
Cycloheximide EXPLODE All
TREES
#64 MESH DESCRIPTOR
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
adj3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin).ab,ti,nm
36 (antifung* or “anti fung*” or
fungastic or fungicidal or Fun-
gizone or Amphocil or Zonal or
Diflucan or Triflucan or hexal
or Fluco* or Flunazul or Fun-
gata or Lavisa or Loitin or Ne-
ofomiral or oxifungol or Sola-
cap or 49858 of Beagyne or
“51211” or Sporanox or Orun-
gal).ab,ti,nm
37 32 or 33 or 34 or 35 or 36
38 31 and 37
or Sirolimus or (Sodium adj3
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
adj3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin).tw
71 (antifung* or “anti fung*” or
fungastic or fungicidal or Fun-
gizone or Amphocil or Zonal or
Diflucan or Triflucan or hexal
or Fluco* or Flunazul or Fun-
gata or Lavisa or Loitin or Ne-
ofomiral or oxifungol or Sola-
cap or 49858 of Beagyne or
“51211” or Sporanox or Orun-
gal).tw
72 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or
38 or 39 or 40 or 41 or 42 or
43 or 44 or 45 or 46 or 47 or
48 or 49 or 50 or 51 or 52 or
53 or 54 or 55 or 56 or 57 or
58 or 59 or 60 or 61 or 62 or
63 or 64 or 65 or 66 or 67 or
68 or 69 or 70 or 71
73 27 and 72
S48 TOPIC: (polyoxin near/3
“D”)
S49 TOPIC: (potassium near/3
iodate)
S50 TOPIC: (posaconazole or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin)
S51 TOPIC: (salicylhydrox-
amic near/3 acid)
S52 TOPIC: (Salicylic near/3
Acid)
S53 TOPIC: (Sch near/3
“39304”)
S54 TOPIC: (saperconazole or
sertaconazole or sinefungin or
Sirolimus)
S55 TOPIC: (Sodium near/3
Benzoate)
S56 TOPIC: (squalestatin or
sulconazole or terbinafine or
terconazole or thermozymo-
cidin or Thymol or tiocona-
zole or Tolnaftate or Tomatine
or Triacetin or trichostatin or
Trimetrexate or troclosene)
S57 TOPIC: (usnic near/3
acid)
S58 TOPIC: (Venturicidins or
vibunazole or voriconazole or
wortmannin)
S59TOPIC: (antifung* or “anti
fung*” or fungastic or fungici-
dal or Fungizone or Amphocil
or Zonal or Diflucan or Triflu-
can or hexal or Fluco* or Flu-
nazul or Fungata or Lavisa or
Loitin or Neofomiral or oxi-
fungol or Solacap or 49858 of
Beagyne or “51211” or Spora-
nox or Orungal)
S60 #59 OR #58 OR #57 OR
#56 OR #55 OR #54 OR #53
OR #52 OR #51 OR #50 OR
#49 OR #48 OR #47 OR #46
OR #45 OR #44 OR #43 OR
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Clotrimazole EXPLODE All
TREES
#65 MESH DESCRIPTOR
Filipin EXPLODE All TREES
#66 MESH
DESCRIPTOR Cerulenin EX-
PLODE All TREES
#67
MESHDESCRIPTORCandi-
cidin EXPLODE All TREES
#68 MESH DESCRIPTOR
Brefeldin A EXPLODE All
TREES
#69 MESH
DESCRIPTOR Benzoates EX-
PLODE All TREES
#70 MESH DESCRIP-
TOR Azaserine EXPLODE All
TREES
#71 MESH DESCRIPTOR
Antimycin A EXPLODE All
TREES
#72 MESH DESCRIPTOR
Amphotericin B EXPLODE
All TREES
#73 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole):TI,AB,
KY
#74 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic near
acid) or (diallyl near trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
or Econazole or Ethonium):TI,
AB,KY
#75 (fenticonazole or ferroin
or Filipin or Flucytosine or
glyphosate or Griseofulvin or
#42 OR #41 OR #40 OR #39
S61 #60 AND #38
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hamycin or Hexetidine or hy-
droxyitraconazole or (ICI near
“195739”) or isoconazole or
Itraconazole or iturin or jas-
plakinolide or Ketoconazole or
lactoferricin or lapachol or law-
sone or leptomycin or Lucen-
somycin):TI,AB,KY
#76 (Mepartricin or methy-
lamphotericin or micafungin
or Miconazole or miltefosine
or Monensin or monorden
or mucidin or muconaldehyde
or Mycobacillin or myxothia-
zol or n-hexanal or naftifine
or Natamycin or Nifuratel or
nikkomycin or nitroxoline or
Nystatin or oxiconazole or
papulacandin or (pelargonic
near acid) or Pentamidine or
polygodial or (polyoxin near
D) or posaconazole or (potas-
sium near iodate) or pradimicin
or protegrin-1 or purothionin
or pyochelin or pyrithione or
Pyrrolnitrin):TI,AB,KY
#77 (rhizoxin or Rutamycin or
(salicylhydroxamic near acid) or
(Salicylic near Acid) or saper-
conazole or (Sch near “39304”)
or sertaconazole or sinefungin
or Sirolimus or (Sodium near
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
near acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin):TI,AB,KY
#78 #32 OR #33 OR #34 OR
#35 OR #36 OR #37 OR #38
OR #39 OR #40 OR #41 OR
#42 OR #43 OR #44 OR #45
OR #46 OR #47 OR #48 OR
#49 OR #50 OR #51 OR #52
OR #53 OR #54 OR #55 OR
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#56 OR #57 OR #58 OR #59
OR #60 OR #61 OR #62 OR
#63 OR #64 OR #65 OR #66
OR #67 OR #68 OR #69 OR
#70 OR #71 OR #72 OR #73
OR #74 OR #75 OR #76 OR
#77
#79 #31 AND #78
CINAHL (EBSCO) ICTRP ClinicalTrials.gov LILACS
S36 S29 AND S35
S35 S30 OR S31 OR S32 OR
S33 OR S34
S34 TX (antifung* or “anti
fung*” or fungastic or fungici-
dal or Fungizone or Amphocil
or Zonal or Diflucan or Triflu-
can or hexal or Fluco* or Flu-
nazul or Fungata or Lavisa or
Loitin or Neofomiral or oxi-
fungol or Solacap or 49858 of
Beagyne or “51211” or Spora-
nox or Orungal)
S33 TX (Candicidin or can-
didin or captax or caspofun-
gin or Cerulenin or ciclopirox
or cilofungin or Clotrimazole
or compactin or cordycepin
or cryptophycin or Cyclohex-
imide or Cyclosporine or (de-
canoic N3 acid) or (diallyl
N3 trisulfide) or Dichlorophen
or diucifon or echinocandin
or Echinocandins or Econa-
zole or Ethonium or fenti-
conazole or ferroin or Fil-
ipin or Fluconazole or Flucy-
tosine or glyphosate or Grise-
ofulvin or hamycin or Hexeti-
dine or hydroxyitraconazole or
(ICI N3 “195739”) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
rhinitis AND fungal OR rhini-
tis AND antifungal OR sinusi-
tis AND fungal OR sinusitis
AND antifungal or CRS AND
fungal OR CRS AND antifun-
gal OR AFRS AND antifun-
gal OR AFRS AND fungal OR
rhinosinusitis AND fungal OR
rhinosinusitis AND antifungal
(rhinitis OR
sinusitis OR rhinosinusitis OR
(nose AND polyps) OR (nasal
ANDpolyps)ORCRSsNPOR
CRSwNP OR CRS OR AFRS)
AND (fungal OR fungastic OR
fungicidal OR Fungizone OR
antifungal OR Amphotericin)
TW:rhinit* OR TW:
sinusit* OR TW:rhinosinusitis
OR TW:rinit* OR (TW:nose
AND TW:polyp*) OR (TW:
nasal AND TW:polyp*) OR
(TW: polipos AND TW:nasa*)
OR TW:CRSsNP OR TW:
CRSwNP OR TW:CRS OR
TW:AFRS
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or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic N3 acid) or Pen-
tamidine or polygodial or (poly-
oxin N3 D) or posaconazole
or (potassium N3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sali-
cylhydroxamicN3 acid) or (Sal-
icylic N3 Acid) or sapercona-
zole or (Sch N3 “39304”) or
sertaconazole or sinefungin or
Sirolimus or (Sodium N3 Ben-
zoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
N3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin)
S32 TX (acivicin or ajoene
or amorolfin or Amphotericin
or anidulafungin or Antimycin
or artemether or aureobasidin
or Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole)
S31 (MH “Mycoses/DT/TH”)
S30
(MH “Antifungal Agents+”) or
(MH “Amphotericin B+”) or
(MH “Antimycin A+”) or (MH
“Azaserine+”) or (MH “Ben-
zoates+”) or (MH “Brefeldin
A+”) or (MH “Candicidin+”)
or (MH “Cerulenin+”) or (MH
“Clotrimazole+”) or (MH “Cy-
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cloheximide+”) or (MH “Cy-
closporine+”)
or (MH “Dichlorophen+”) or
(MH “Echinocandins+”) or
(MH “Econazole+”) or (MH
“Filipin+”) or (MH “Flucona-
zole+”)
or (MH “Flucytosine+”) or
(MH “Griseofulvin+”) or (MH
“Hexetidine+”) or (MH “Itra-
conazole+”) or (MH “Keto-
conazole+”) or (MH “Lucen-
somycin+”) or (MH “Mepar-
tricin+”) or (MH “Micona-
zole+”) or (MH “Monensin+”)
or (MH “Mycobacillin+”) or
(MH “Natamycin+”) or (MH
“Nifuratel+”)
or (MH “Nystatin+”) or (MH
“Pentamidine+”) or (MH “Ru-
tamycin+”) or (MH “Salicylic
Acid+”) or (MH “Sirolimus+”)
or (MH “Sodium Benzoate+”)
or (MH “Thymol+”) or (MH
“Tomatine+”) or (MH “Tolnaf-
tate+”) or (MH“Triacetin+”) or
(MH “Trimetrexate+”) or (MH
“Venturicidins+”)
S29 S18 OR S19 OR S20 OR
S21 OR S26 OR S27 OR S28
S28 TX (rhinopolyp* or CR-
SwNP)
S27 TX ((nose or nasal or
rhino* or rhinitis or sinus* or
sinonasal) N3 (papilloma* or
polyp* or fung*))
S26 S24 AND S25
S25 (MH “Polyps+”)
S24 S22 OR S23
S23 (MH “Nose Diseases+”)
S22 (MH “Nose+”)
S21 (MH “Rhinitis+/MI”) OR
(MH “Nasal Mucosa+/MI”)
S20 (MH “Paranasal Sinus Dis-
eases+/MI”) OR (MH
“Paranasal Sinuses+/MI”)
S19 (MH “Nasal Polyps+”)
S18 S15 OR S16 OR S17
S17 TX ((sinusitis or rhinitis)
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n3 (chronic or persis* or recur-
rent* or fung*))
S16 TX (CRSsNP or AFS or
AFRS)
S15 S8 AND S14
S14 S9 OR S10 OR S11 OR
S12 OR S13
S13 TX (chronic or persis*
or recurrent* or fung* or
eosinophil* or mycetoma* or
Maduromycos* or Actinomyce-
toma* or Eumycetoma*)
S12 (MH “Mycetoma+”)
S11 (MH “Fungi+”)
S10 (MH “Chronic Disease+”)
S9 (MH “Recurrence+”)
S8 S1ORS2ORS3ORS4OR
S5 OR S6 OR S7
S7TX ((maxilla* or frontal*) n3
sinus*)
S6 TX (inflamm* n3 sinus*)
S5 TX kartagener* n3 syn-
drome*
S4 TX rhinosinusitis or nasos-
inusitis or pansinusitis or eth-
moiditis or sphenoiditis
S3 (MH “Paranasal Sinus Dis-
eases+”)
S2 (MH “Paranasal Sinuses+”)
S1 (MH “Rhinitis+”)
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
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General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
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• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Presence of allergic fungal rhinosinusitis: x% with AFRS
[add info if available]
• Presence of eosinophilic CRS: x% with eosinophilic CRS
[add info if available]
• Previous sinus surgery status: [x% with previous surgery
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects (systemic antifungals): hepatic
toxicity
Secondary outcomes:
• Health-related quality of life, generic
• Adverse effects (topical antifungals): epistaxis, headache,
local discomfort (mild burning, itching)
• Adverse effects (systemic antifungals): gastrointestinal
disturbances, allergic reactions.
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
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(Continued)
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
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(Continued)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Renal/hepatic
toxicity
Systemic
antifungals
Headache Topical antifun-
gals
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
Topical antifun-
gals
Systemic
antifungals
Epistaxis Topical antifun-
gals
Local discomfort Topical antifun-
gals
Anaphy-
laxis or other se-
rious allergic re-
actions
Systemic
antifungals
Comments:
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This review will update and replace the previously published review ’Topical and systemic antifungal therapy for the symptomatic
treatment of chronic rhinosinusitis’ (Sacks 2011).
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